Government funding of fluorodeoxyglucose positron emission tomography (FDG-PET) in rare urological cancers: better data, better outcomes
Corresponding Author
Jennifer Xu
Department of Urology, Royal Melbourne Hospital, Parkville, Vic., Australia
Correspondence: Jennifer Xu, Department of Urology, Royal Melbourne Hospital, 300 Grattan Street, Parkville, Vic. 3050, Australia.
e-mail: [email protected]
Search for more papers by this authorHaidar Al Saffar
Department of Uro-Oncology, Peter MacCallum Cancer Centre, Parkville, Vic., Australia
Search for more papers by this authorJonathan O'Brien
Department of Uro-Oncology, Peter MacCallum Cancer Centre, Parkville, Vic., Australia
Search for more papers by this authorBrian Kelly
Department of Uro-Oncology, Peter MacCallum Cancer Centre, Parkville, Vic., Australia
Search for more papers by this authorNathan Lawrentschuk
Department of Urology, Royal Melbourne Hospital, Parkville, Vic., Australia
Department of Uro-Oncology, Peter MacCallum Cancer Centre, Parkville, Vic., Australia
Search for more papers by this authorCorresponding Author
Jennifer Xu
Department of Urology, Royal Melbourne Hospital, Parkville, Vic., Australia
Correspondence: Jennifer Xu, Department of Urology, Royal Melbourne Hospital, 300 Grattan Street, Parkville, Vic. 3050, Australia.
e-mail: [email protected]
Search for more papers by this authorHaidar Al Saffar
Department of Uro-Oncology, Peter MacCallum Cancer Centre, Parkville, Vic., Australia
Search for more papers by this authorJonathan O'Brien
Department of Uro-Oncology, Peter MacCallum Cancer Centre, Parkville, Vic., Australia
Search for more papers by this authorBrian Kelly
Department of Uro-Oncology, Peter MacCallum Cancer Centre, Parkville, Vic., Australia
Search for more papers by this authorNathan Lawrentschuk
Department of Urology, Royal Melbourne Hospital, Parkville, Vic., Australia
Department of Uro-Oncology, Peter MacCallum Cancer Centre, Parkville, Vic., Australia
Search for more papers by this author
References
- 1Kelly BD, Perera M, Bolton DM, Papa N. Social determinants of health: does socioeconomic status affect access to staging imaging for men with prostate cancer. Prostate Cancer Prostatic Dis 2022; 26: 429–431
- 2Society AC. Statistics for penile cancer. Available at: https://www.cancer.org/cancer/penile-cancer/about/key-statistics.html. Accessed November 2022
- 3Schlenker B, Scher B, Tiling R et al. Detection of inguinal lymph node involvement in penile squamous cell carcinoma by 18F-fluorodeoxyglucose PET/CT: a prospective single-center study. Urol Oncol 2012; 30: 55–59
- 4Salem AE, Fine GC, Covington MF et al. PET-CT in clinical adult oncology-IV. Gynecologic and genitourinary malignancies. Cancers (Basel) 2022; 14: 3000
- 5Park JS, Kim J, Elghiaty A, Ham WS. Recent global trends in testicular cancer incidence and mortality. Medicine (Baltimore) 2018; 97: e12390
- 6Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin 2021; 71: 7–33